I spoke with @bruce_sands1 Chief of Gastroenterology at @MountSinaiGI about a potential new #IBD treatment that targets TWO pathways in ONE injection 💉 It could be a game-changer for patients who’ve run out of options for both #Crohns & #UC
Watch the highlights ⬇️
I was proud to present Phase 2b results from the DUET-UC trial at @DDWMeeting 2026, showing that a novel dual-antibody therapy targeting IL-23 & TNF produced stronger outcomes than either drug alone in patients with treatment-resistant #UlcerativeColitis. https://t.co/aPcEWaWeza
#Mentalhealth matters…especially for those of us living with #IBD 🧠The journey can be heavy, but finding moments of peace can help us reconnect with ourselves. La #saludmental importa, especialmente para quienes vivimos con la #EII#MentalHealthAwarenessMonth
#WorldIBDDay | #DíaMundialDeLaEII#IBD has no borders🌎
La #EII no tiene fronteras🌎
As a #Latina living w/ #Crohns I know advocacy can bridge what borders often divide-through languages & across cultures. Let’s build a 🌎 w/out borders in care, compassion & understanding!
This #WorldIBDDay the @CrohnsColitisFn created a free guide-More Than the Gut-to help navigate the mental & emotional side of living w/ #IBD En honor al Día Mundial de la #EII la Fundación creó una guía gratuita-Más allá del intestino-para ayudarnos a enfrentar la EII 📝
Bowel urgency #BU 😖🚽💩is an under recognized debilitating symptom amongst patients with IBD
📻Tune in tomorrow for @AmCollegeGastro virtual grand rounds for a presentation on #BU moderated 👨⚖️ by @ibdtweets
➡️ https://t.co/0Ixps3kK0I
As we approach #WorldIBDDay we’re reminded #IBD has no borders. Living w/ #Crohns or #UC can be isolating, but support connects us. Our #Spanish virtual IBD #supportgroup is a space to share & feel understood. Next group is on Monday, 5/18 for Spanish speaking IBD patients!
🔗👇🏼
Thank you @SenatorChoi for taking the time to listen to my Crohn’s disease journey & being open to understanding the reasons why SB-964 is so important! Dose optimization should NOT require prior authorizations 😠 #IBDAdvocacy#SB964#DoseOptimization#IBD
I spoke with @bruce_sands1 Chief of Gastroenterology at @MountSinaiGI about a potential new #IBD treatment that targets TWO pathways in ONE injection 💉 It could be a game-changer for patients who’ve run out of options for both #Crohns & #UC
Watch the highlights ⬇️
So valuable to hear @KenCroitoru speak on pre-clinical disease & primary targets for prevention of #IBD It is so encouraging to know there is a continued focus on preventing #IBD while concurrently treating patients today with advanced therapies!
#DDW2026
Incredible session by @RobertHirten re: real-time monitoring in #IBD & how to integrate into patient care, as well as understanding in which populations it should be use. Goal is to demonstrate impact on outcomes, quality of life, fewer flares & lower costs
I had the honor of interviewing @bruce_sands1 re: a new #IBD therapy (stay tuned!) & in today’s lecture he shared a number of emerging therapies & therapeutic strategies reaching the clinic. So much has evolved in the last 20 years! 🙌🏼 #DDW2026
Thank you @vipuljairath for discussing ways to optimize #clinicaltrial design & how to move forward. So much work to be done to focus on neglected #IBD subtypes & increasing #diversity & access to trials, as well as integrating novel #PROs & #endpoints#DDW2026
My final session of #DDW2026 is a state of the art lecture of 5 expert speakers reviewing novel endpoints for the treatment of #IBD & treatments in development. Novel monitoring strategies & emerging disease areas are being discussed. It is the BEST time to be living with IBD🎉
In the GALAXI 2 & 3 LTE, GUS 200 q4w dose adjustment was evaluated for #CD pts with inadequate response. Maintenance dose adjustment to guselkumab 200 mg q4w may benefit patients with Crohn's disease who experience inadequate response to guselkumab 100 mg q8w 👍🏼 #DDW2026
At #DDW2026#Ustekinumab induction & maintenance therapy was found to be. effective in treating #pediatric#IBD patients aged 2 to <18 years with moderately to severely active ulcerative colitis! Huge win for #PedsGI 🙌🏼
Dr. Gulhati presented at #DDW2026 on the role of fecal calprotectin #FCP & color Doppler signal correlated on #IUS in small bowel strictures which together are demonstrated to be a strong marker of active inflammation in #strictures